Press release
Deadline on August 05, 2024 coming up in Lawsuit for Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)
A Deadline is coming up on August 5, 2024 in the lawsuit for certain investors in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS).
Investors who purchased shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) have certain options and there are strict and short deadlines running. Deadline: August 5, 2024. NASDAQ: MRNS stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges on behalf of purchasers of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) common shares between March 17, 2021 and May 7, 2024, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 17, 2021 and May 7, 2024, the defendants made materially false and/or misleading statements and/or failed to disclose that defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial, that defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times
Those who purchased shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on August 05, 2024 coming up in Lawsuit for Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) here
News-ID: 3611281 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Marinus
Status Epilepticus Market Exclusive Report with Detailed Study Analysis | SAGE T …
The qualitative latest Research report (2025-2032) on the Status Epilepticus Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/4706
Focused on growth and…
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States …
The Key CDKL5 Deficiency Disorder Companies in the market include - Marinus Pharmaceuticals, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharmaceutical Inc. and others.
DelveInsight's "CDKL5 Deficiency Disorder Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the CDKL5 Deficiency Disorder, historical and forecasted epidemiology as well as the CDKL5 Deficiency Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare…
Lawsuit Alert: Investors who lost money with shares of Marinus Pharmaceuticals, …
An investor, who purchased shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), filed a lawsuit over alleged violations of Federal Securities Laws by Marinus Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) have certain options and for certain investors are short and strict deadlines running. Deadline: August 5, 2024. NASDAQ: MRNS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Status Epilepticus Market Share ,Size, Growth, and Forecast By 2024-2031| SAGE …
The "Status Epilepticus Market was valued for $6.5 billion in 2024 and is estimated to reach $18.5 billion by 2031, exhibiting a CAGR of 11.2% from 2024 to 2031.
Coherent Market Insights has released a statistical report titled "Status Epilepticus Market Recent Trends, In-depth Analysis, Size, and Forecast 2024-2031." This report offers a comprehensive overview of the competitive landscape, geographical segmentation, innovation, future developments, and a compilation of tables and data.…
Status Epilepticus Market Size, Share, Emerging Trends, Key Growth Drivers, Chal …
Status Epilepticus Market Report presents a comprehensive overview of the market by product types, applications, major companies and key regions and countries, market share and growth opportunities. The report also presents a detailed analysis of the competitive landscape of the market and the major providers in the market. The report describes in-depth assessments and professional studies on the current state of the Status Epilepticus market, including key facts and figures.…
Status Epilepticus Market See Incredible Growth 2022-2028 | SAGE Therapeutics, …
The exclusive research report on 'Status Epilepticus Market' now available with 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, offers a detailed analysis of the factors influencing the global business sphere. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Status Epilepticus Market.
The research report incorporates a detailed evaluation…
